Compare PSQH & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | TVRD |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 27.5M |
| IPO Year | 2021 | 2013 |
| Metric | PSQH | TVRD |
|---|---|---|
| Price | $3.39 | $1.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | 38.6K | ★ 228.3K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.00 | ★ 79.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,685,987.00 | $911,000.00 |
| Revenue This Year | $81.45 | N/A |
| Revenue Next Year | $35.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1096.61 | 959.30 |
| 52 Week Low | $0.36 | $0.93 |
| 52 Week High | $6.94 | $6.43 |
| Indicator | PSQH | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 32.83 |
| Support Level | $0.51 | $0.93 |
| Resistance Level | $5.73 | $2.02 |
| Average True Range (ATR) | 0.35 | 0.08 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 5.61 | 17.78 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.